Comparison · NCT03289910-9c441e86
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Still Alive at Study Completion
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Still Alive at Study Completion. Trial comparisons, record NCT03289910-9c441e86. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03289910-9c441e86
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.313 | 0.142 | 0.556 | wilson | |
| Risk in group 2 | 0.556 | 0.267 | 0.811 | wilson | |
| Risk difference, group 1 minus group 2 | -0.243 | -0.551 | 0.135 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.563 | 0.221 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 0.364 | 0.0673 | 1.96 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) than on Arm B (Topotecan Hydrochloride, Carboplatin) | 4.11 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) | Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. | 5 | 16 | OG000 |
| Group 2 | Arm B (Topotecan Hydrochloride, Carboplatin) | Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. | 5 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Still Alive at Study Completion
- Description
- Study completion was either death or completion of all protocol-specified activities, whichever came first.
- Time frame
- Up to 7 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
- NCT number
- NCT03289910
- Phases
- PHASE2
- Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2024-04-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03289910?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03289910-9c441e86